Q-omics provides the consensus-scored PCSK5 profile across patient tissues and cancer cell-line models. PCSK5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PCSK5 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, PCSK5 RNA expression shows 17,192 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where PCSK5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCSK5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCSK5 survival associations across molecular data types. PCSK5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCSK5 RNA expression–survival associations across cancer types. High PCSK5 expression shows unfavorable associations in KIRP, BLCA, COAD and STAD, but favorable associations in KIRC and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PCSK5 RNA expression.
This table summarizes PCSK5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PCSK5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCSK5 shows lower tumor expression in COAD, KICH, LUAD, BRCA and BLCA and higher tumor expression in LIHC. The COAD box plot shows higher PCSK5 RNA expression in normal versus tumor tissue (log2 FC = −2.287, t-test p < 0.001).
This table shows molecular features associated with PCSK5 in patient tissues and cancer cell lines. In patient samples, PCSK5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCSK5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
